ALDEYRA THERAPEUTICS, INC. (ALDX) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -24.07M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | 15.63M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-24.07M | (m) | (m) | $15.63M | (m) | (m) |
| 2026-03-31 | $-28.38M | (m) | (m) | $20.65M | (m) | (m) |
| 2025-12-31 | $-35.27M | (m) | (m) | $25.66M | (m) | (m) |
| 2025-09-30 | $-45.18M | (m) | (m) | $35.99M | (m) | (m) |
| 2025-06-30 | $-53.31M | (m) | (m) | $43.00M | (m) | (m) |
| 2025-03-31 | $-61.15M | (m) | (m) | $49.46M | (m) | (m) |
| 2024-12-31 | $-60.12M | (m) | (m) | $48.22M | (m) | (m) |
| 2024-09-30 | $-49.64M | (m) | (m) | $37.89M | (m) | (m) |
| 2024-06-30 | $-43.05M | (m) | (m) | $32.41M | (m) | (m) |
| 2024-03-31 | $-35.38M | (m) | (m) | $24.41M | (m) | (m) |
| 2023-12-31 | $-42.79M | (m) | (m) | $29.46M | (m) | (m) |
| 2023-09-30 | $-50.39M | (m) | (m) | $34.12M | (m) | (m) |
| 2023-06-30 | $-55.63M | (m) | (m) | $38.70M | (m) | (m) |
| 2023-03-31 | $-63.00M | (m) | (m) | $46.31M | (m) | (m) |
| 2022-12-31 | $-62.68M | (m) | (m) | $47.31M | (m) | (m) |
| 2022-09-30 | $-64.39M | (m) | (m) | $51.19M | (m) | (m) |
| 2022-06-30 | $-65.04M | (m) | (m) | $52.54M | (m) | (m) |
| 2022-03-31 | $-61.87M | (m) | (m) | $49.44M | (m) | (m) |
| 2021-12-31 | $-56.22M | (m) | (m) | $44.94M | (m) | (m) |
| 2021-09-30 | $-52.10M | (m) | (m) | $39.12M | (m) | (m) |
| 2021-06-30 | $-45.05M | (m) | (m) | $32.36M | (m) | (m) |
| 2021-03-31 | $-37.61M | (m) | (m) | $25.77M | (m) | (m) |
| 2020-12-31 | $-36.42M | (m) | (m) | $24.68M | (m) | (m) |
| 2020-09-30 | $-38.03M | (m) | (m) | $27.27M | (m) | (m) |
| 2020-06-30 | $-48.66M | (m) | (m) | $37.36M | (m) | (m) |
| 2020-03-31 | $-55.28M | (m) | (m) | $43.14M | (m) | (m) |
| 2019-12-31 | $-63.07M | (m) | (m) | $44.35M | (m) | (m) |
| 2019-09-30 | $-61.27M | (m) | (m) | $43.29M | (m) | (m) |
| 2019-06-30 | $-53.20M | (m) | (m) | $34.94M | (m) | (m) |
| 2019-03-31 | $-48.64M | (m) | (m) | $31.07M | (m) | (m) |
| 2018-12-31 | $-39.70M | (m) | (m) | $29.82M | (m) | (m) |
| 2018-09-30 | $-35.65M | (m) | (m) | $26.82M | (m) | (m) |
| 2018-06-30 | $-29.72M | (m) | (m) | $22.48M | (m) | (m) |
| 2018-03-31 | $-25.88M | (m) | (m) | $19.53M | (m) | (m) |
| 2017-12-31 | $-22.49M | (m) | (m) | $16.30M | (m) | (m) |
| 2017-09-30 | $-20.09M | (m) | (m) | $14.20M | (m) | (m) |
| 2017-06-30 | $-19.86M | (m) | (m) | $14.05M | (m) | (m) |
| 2017-03-31 | $-18.82M | (m) | (m) | $13.03M | (m) | (m) |
| 2016-12-31 | $-18.70M | (m) | (m) | $13.18M | (m) | (m) |
| 2016-09-30 | $-18.38M | (m) | (m) | $12.84M | (m) | (m) |
| 2016-06-30 | $-16.94M | (m) | (m) | $11.53M | (m) | (m) |
| 2016-03-31 | $-14.85M | (m) | (m) | $9.95M | (m) | (m) |
| 2015-12-31 | $-11.99M | (m) | (m) | $7.57M | (m) | (m) |
| 2015-09-30 | $-10.06M | (m) | (m) | $5.87M | (m) | (m) |
| 2015-06-30 | $-8.69M | (m) | (m) | $4.98M | (m) | (m) |
| 2015-03-31 | $-8.13M | (m) | (m) | $4.40M | (m) | (m) |
| 2014-12-31 | $-7.27M | (m) | (m) | $3.71M | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-3.68M | (m) | (m) | $1.54M | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |